Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study

PURPOSE: To examine efficacy and safety of paliperidone palmitate (PP) 6-month (PP6M) vs PP3-month (PP3M) long acting injectable (LAI) in patients with schizophrenia from European sites previously stabilized on PP3M or PP1-month (PP1M). METHODS: This post-hoc subgroup analysis used data from a globa...

Descripción completa

Detalles Bibliográficos
Autores principales: Giron‐Hernandez, Cesar, Han, Joong Hee, Alberio, Roberta, Singh, Arun, García-Portilla, Maria Paz, Pompili, Maurizio, Knight, R Karl, Richarz, Ute, Gopal, Srihari, Antunes, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108905/
https://www.ncbi.nlm.nih.gov/pubmed/37077705
http://dx.doi.org/10.2147/NDT.S400342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108905/
https://www.ncbi.nlm.nih.gov/pubmed/37077705
http://dx.doi.org/10.2147/NDT.S400342

Ejemplares similares